Apollo Therapeutics’ Post

Today is “World Parkinson’s Day” and EDELRIS is pleased to share its latest contribution to Parkinson’s drug discovery: In 1817 Dr. James Parkinson published “An Essay on the Shaking Palsy” which first recognized Parkinson’s as a medical condition. April 11th is “World Parkinson’s Day” in commemoration of the birthday of Dr. James Parkinson, but also to raise awareness of Parkinson’s. Since 1817 a lot of research has been done to alleviate and treat this handicapping condition, but there is still a high medical need. Today, Edelris' Medicinal Chemistry Team is excited and humbled to announce that our research efforts have contributed to the selection of a preclinical candidate for Parkinson's. Cross-fertilizing efforts with our project partners ARGOBIO, GeneCode, University of Helsinki, and Evotec, we reached a significant milestone on a challenging medicinal chemistry project for an innovative therapeutic approach to Parkinson’s disease. Edelris’ team of medicinal chemists efficiently managed to solve ADME liabilities of hit compounds, to deliver novel lead series protected by two patent applications. This two-year-long medicinal chemistry collaboration allows the project team to select a preclinical candidate with neurotrophic and neuroprotective effects on human dopaminergic neurons. For Edelris, contributing as medicinal- and analytical chemistry experts to this challenging Parkinson’s discovery project within a network of partners is second nature!  https://lnkd.in/eyu-mmdP https://lnkd.in/gJF5yBbn #drugdicovery #medicinalchemistry #parkinson’s #innovation

SPONSORED: At the University of Cincinnati, research and innovation are at the forefront of what we do. The online drug development master’s degree provides an in-depth and formal education around drug development’s complex science and processes. The online pharmacogenomics and personalized healthcare master’s degree offers a unique opportunity for students to gain in-depth knowledge about Pharmacogenomics and understand the effects of genomics, environment, patient-specific factors on drug response, allowing for individualized therapy and optimal clinical outcomes. https://smpl.is/8mj9s

Is Structure Therapeutics, the Up Start GLP-1 Receptor Developer A Target--Their Phase 2 Data Looks Promising https://lnkd.in/eYp985v5

We’re looking forward to taking a group of leading biotech companies to #Sweden next week as part of Innovate UK’s Global Business Innovation Programme on Advanced Therapy Medicinal Products (ATMP). We’ll be meeting a wide range of contacts to forge collaboration between our delegates and Swedish partners in this key sector.  Our visit highlights the ever-growing relationship between the UK and Sweden - in 2022, the UK and Sweden signed a joint MOU on health and life sciences, highlighting ATMP as a priority. We’ll visit the Karolinska Institutet and the KTH Royal Institute of Technology, we'll learn about new ATMP facilities in Flemingsberg and Gothenburg, and will be seeing the renowned Sahlgrenska University Hospital and the Lund University Stem Cell Centre.  And we'll be meeting lots of ATMP experts along the way to explore the considerable opportunities. Unicorn Biotechnologies Stratosvir Limited StemBond Technologies Rinri Therapeutics ReproGO Lentitek MicrofluidX iLoF Deliver Biosciences Exogene Astral Systems Clara King Ying Gao Isabel Save Louise Hooker Saba Hussein Gore, PhD Kate Orrick MBE Richard Cowburn Viktor Olsson Andreas Muranyi Scheutz Johnny Högberg Matti Sallberg Iris Öhrn Anna Redwood Kristina Levan    #GBIP #genetherapy #celltherapy #ATMP #biotechnology #clinicalresearch #cellandgenetherapy #medtech #processtechnologies #bioprocessing Innovate UK Innovate UK South West  

The Essential Role of Wet Lab Work in Pharmacological and Biomedical Research In the rapidly advancing fields of pharmacology and biomedicine, wet lab work is the core of translating theories into therapies. From culturing cells to testing drug interactions, hands-on experimentation is where we truly witness the impact of our hypotheses on real-world applications. In 2024, Current researchers focus lies on bacterial research involving human pathogens and antimicrobial resistance—two critical areas demanding precision and dedication. As we push boundaries in understanding microbial dynamics, the insights we gain pave the way for stronger, more resilient healthcare interventions. Working with these complex systems isn’t just science—it’s the foundation for tomorrow’s cures.

Breakthroughs in Drug Discovery 👨🔬 👩🔬 Did you know? Drug discovery is a complex process that can take over a decade from initial research to market approval. Scientists use cutting-edge techniques like high-throughput screening and computer-aided drug design to identify promising compounds that can treat various diseases. It’s a meticulous journey from lab to pharmacy! #BRAINING European Commission, Jagiellonian University, Hospital del Mar Research Institute, Faculdade de Medicina da Universidade de Lisboa, University of Salamanca (Universidad de Salamanca)

Healthcare Everything magazine gladly features Dimitrios Karamichos, Executive Director and Endowed Chair of the North Texas Eye Research Institute, the Interim Dean of the School of Biomedical Sciences and professorships in Pharmaceutical Sciences and Pharmacology & Neurosciences at University of North Texas Health Science Center College of Public Health. He has deep scientific expertise and leadership skills, fostering a dynamic environment where research and education thrive together. Read More: https://cutt.ly/zeI9kcQR #OcularSciences #HealthcareEverything #DimitriosKaramichos #BestHealthcareDigitalMagazine #TopHealthandWellnessMagazines #HealthcareTechMagazine

Seeking Funding for a #TranslationalScience Project? The Small Grants to Advance Translational Science (S-GATS) Program is offering awards of up to $50,000 to support innovative and collaborative projects aimed at advancing the science of translation. The program is designed to address critical challenges in translational research across various diseases and health conditions, while also encouraging the exploration of novel opportunities and pathways. It welcomes projects that target specific translational challenges—such as improving predictions of drug toxicity or efficacy, enhancing data interoperability, or optimizing clinical trial recruitment—as well as those that seek to leverage untapped opportunities within the field. The application process begins with the submission of a competitive Letter of Intent, due by Tuesday, October 8, 2024. If invited, a full proposal will be required by Thursday, December 19, 2024. To ensure that proposed research projects align with the 2025 request for applications, prospective applicants must consult with the S-GATS Program team prior to submitting their Letter of Intent. An information session will be held tomorrow (Thursday, September 12) @ 4PM! For consultation scheduling, registration for the information sessions, or any inquiries, please contact Nadia Prokofieva, MSSc, at sgats@tuftsmedicine.org. Additional information about this funding opportunity can be found on the Tufts CTSI S-GATS Program page. https://lnkd.in/dt4fhKBf Tufts Medical Center Tufts Medicine Tufts University

Reproducibility matters! “If you publish something that’s not reproducible, it's negatively impacting drug discovery. It's not going to create therapies for any patient.” Read my full comments along with other experts in the field in this SLAS article.

One small detail makes all the difference between a reproducible experiment and one that is not, according to Robert Campbell, Ph.D., editor-in-chief of SLAS Discovery: Advancing the Science of Drug Discovery. Campbell comments in a recent SLAS Electronic Laboratory Neighborhood article that reproducibility is rooted in appropriate experimental design, well-described methods, and inclusion of all pertinent details – particularly when scientists enter the publishing process. In the same article, Kenda LJ Evans, Ph.D., of Agilent Technologies (Santa Clara, CA, USA), and co-chair for the SLAS Screen Design and Assay Technology Topical Interest Group (TIG), comments: “The challenges of reproducibility are not going to go away. We need it when we’re making go/no-go decisions. If you don’t have good reproducibility, it’s hard to know what’s a true result and what’s a false-positive. I think that talking about reproducibility and finding better ways of achieving it in our assays is crucial to drug discovery and research.” Read what other subject matter experts have to say in the article: https://lnkd.in/gNEspcne.